Pyoderma gangrenosum: A clinico-epidemiological study

被引:9
作者
Riyaz, Najeeba [1 ]
Mary, Vineetha [3 ]
Sasidharanpillai, Sarita [1 ]
Roshin, Riyaz A. [4 ]
Snigdha, Ottakandathil [2 ]
Latheef, Ettappurath N. Abdul [1 ]
Rahima, Saleem [1 ]
Bindu, Valiaveetil [1 ]
Anupama, Ravindran N. [5 ]
Sureshan, Deepthi N. [1 ]
Sherjeena, Pentam Veil Beegum [1 ]
机构
[1] Govt Med Coll, Dept Dermatol, Kozhikode, India
[2] Lisa Skin Clin, Dept Dermatol, Kozhikode, India
[3] Govt Med Coll, Dept Dermatol, Kottayam, Kerala, India
[4] Amina Hosp, Dept Dermatol, Perinthalmanna, India
[5] Valluvanad Hosp, Dept Dermatol, Ottappalam, Kerala, India
关键词
Dexamethasone pulse therapy; intravenous immunoglobulin G; pyoderma gangrenosum; systemic association;
D O I
10.4103/0378-6323.188654
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Pyoderma gangrenosum is a neutrophilic dermatosis of unknown etiology, with inconstant systemic associations and a variable prognosis. Aims: To study the clinical features and systemic associations of pyoderma gangrenosum and its response to treatment. Methods: All patients diagnosed to have pyoderma gangrenosum at the dermatology department of the Government Medical College, Kozhikode, from January 01, 2005 to December 31, 2014 were included in this prospective study. Results: During the 10-year study period, 61 patients were diagnosed to have pyoderma gangrenosum. A male predilection was noted. The most common clinical type was ulcerative pyoderma gangrenosum (90.2%). More than 60% of patients had lesions confined to the legs; 78.7% had a single lesion and 27.9% had systemic associations. Most patients required systemic steroids. Patients with disease resistant to steroid therapy were treated with intravenous immunoglobulin G and split-thickness skin grafts under immunosuppression induced by dexamethasone pulse therapy. All except one patient attained complete disease resolution. Limitations: The main limitation of our study was the small sample size. Conclusions: The male predilection documented by us was contrary to most previous studies. We found split-thickness skin graft to be a useful option in resistant cases. More prospective studies may enable the formulation of better diagnostic criteria for pyoderma gangrenosum and improve its management.
引用
收藏
页码:33 / 39
页数:7
相关论文
共 50 条
  • [31] Pyoderma Gangrenosum: Recognition and Management
    Pompeo, Matthew Q.
    WOUNDS-A COMPENDIUM OF CLINICAL RESEARCH AND PRACTICE, 2016, 28 (01): : 7 - 13
  • [32] Extracutaneous involvement of pyoderma gangrenosum
    Luis J. Borda
    Lulu L. Wong
    Angelo V. Marzano
    Alex G. Ortega-Loayza
    Archives of Dermatological Research, 2019, 311 : 425 - 434
  • [33] Pyoderma gangrenosum: a systematic review
    Cozzani, E.
    Gasparini, G.
    Parodi, A.
    GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA, 2014, 149 (05): : 587 - 600
  • [34] Adalimumab for treatment of pyoderma gangrenosum
    Pomerantz, R. G.
    Husni, M. E.
    Mody, E.
    Qureshi, A. A.
    BRITISH JOURNAL OF DERMATOLOGY, 2007, 157 (06) : 1274 - 1275
  • [35] Wound Debridement in Pyoderma Gangrenosum
    Taheri, Arash
    Mansoori, Parisa
    Sharif, Mohammad
    ADVANCES IN SKIN & WOUND CARE, 2024, 37 (02) : 107 - 111
  • [36] Pyoderma Gangrenosum: A Review for the Gastroenterologist
    Plumptre, Isabella
    Knabel, Daniel
    Tomecki, Kenneth
    INFLAMMATORY BOWEL DISEASES, 2018, 24 (12) : 2510 - 2517
  • [37] An update on adalimumab for pyoderma gangrenosum
    Yamamoto, T.
    DRUGS OF TODAY, 2021, 57 (09) : 535 - 542
  • [38] Pathergy in a patient with pyoderma gangrenosum
    Kurimoto, Toru
    Mitsui, Yasuhiro
    JOURNAL OF DERMATOLOGY, 2024, 51 (02) : e29 - e30
  • [39] Surgical management of Pyoderma gangrenosum
    Sick, I.
    Trautner, B.
    Ruzicka, T.
    HAUTARZT, 2012, 63 (07): : 577 - 583
  • [40] Emerging treatments for pyoderma gangrenosum
    Wollina, Uwe
    EXPERT OPINION ON ORPHAN DRUGS, 2017, 5 (10): : 827 - 832